N of 1 trials in diabetes: making individual therapeutic decisions
- PMID: 18389212
- DOI: 10.1007/s00125-008-0983-2
N of 1 trials in diabetes: making individual therapeutic decisions
Abstract
N of 1 trials are single-subject, randomised, crossover studies, in which the patient serves as their own control to compare the efficacy of a treatment. They offer an alternative to large, randomised clinical trials, which have limited applicability, and empirical testing, which is arbitrary in nature. N of 1 trials are regarded as providing the highest strength of evidence for individual subject decisions. They rely upon the patient expressing preferences and making shared decisions for determining the future therapy, and may therefore lead to the successful implementation of lifestyle interventions. N of 1 trials are an optimal approach for making therapeutic decisions in chronic diseases like diabetes mellitus, where decision-making is often reliant upon arbitrary criteria and clinical judgement.
Similar articles
-
[Blood pressure control in patients with diabetes mellitus. Focus on postprandial blood glucose values and cardiovascular risk].MMW Fortschr Med. 2012 Feb 23;154(3):82-3. MMW Fortschr Med. 2012. PMID: 22458177 German. No abstract available.
-
An update on the long-acting insulin analogue glargine.Basic Clin Pharmacol Toxicol. 2006 Jul;99(1):1-11. doi: 10.1111/j.1742-7843.2006.pto_352.x. Basic Clin Pharmacol Toxicol. 2006. PMID: 16867163 Review.
-
Ready for anything. How to be prepared in case of severe highs or lows.Diabetes Forecast. 2012 Apr;65(4):38, 41. Diabetes Forecast. 2012. PMID: 22582522 No abstract available.
-
The pharmacological treatment of hyperglycemia in NIDDM. American Diabetes Association.Diabetes Care. 1995 Nov;18(11):1510-8. doi: 10.2337/diacare.18.11.1510. Diabetes Care. 1995. PMID: 8722084 Review. No abstract available.
-
Optimizing glycemic control with insulin glargine.Diabetes Technol Ther. 2003;5(3):471-3. doi: 10.1089/152091503765692009. Diabetes Technol Ther. 2003. PMID: 12828834 No abstract available.
Cited by
-
Antidiabetic treatment: Though lovers be lost, love shall not.World J Diabetes. 2012 Sep 15;3(9):158-60. doi: 10.4239/wjd.v3.i9.158. World J Diabetes. 2012. PMID: 23125905 Free PMC article.
-
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetes Care. 2012 Jun;35(6):1364-79. doi: 10.2337/dc12-0413. Epub 2012 Apr 19. Diabetes Care. 2012. PMID: 22517736 Free PMC article. Review. No abstract available.
-
Using N-of-1 trials to improve patient management and save costs.J Gen Intern Med. 2010 Sep;25(9):906-13. doi: 10.1007/s11606-010-1352-7. Epub 2010 Apr 13. J Gen Intern Med. 2010. PMID: 20386995 Free PMC article. Clinical Trial.
-
Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin.Diabetes Metab Syndr Obes. 2019 Dec 3;12:2549-2557. doi: 10.2147/DMSO.S190356. eCollection 2019. Diabetes Metab Syndr Obes. 2019. PMID: 31819580 Free PMC article. Review.
-
Translation of personalized decision support into routine diabetes care.J Diabetes Sci Technol. 2010 Nov 1;4(6):1532-9. doi: 10.1177/193229681000400631. J Diabetes Sci Technol. 2010. PMID: 21129352 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical